Evidence map›Paper›PMID 33463758›Full record

ArticleJournal of clinical laboratory analysis2020

A novel circulating miRNA-based signature for the early diagnosis and prognosis prediction of non-small-cell lung cancer.

Chengwei Zhou, Zixuan Chen, Lili Zhao, Weijun Zhao, Yonggang Zhu, Jiayuan Liu, Xiaodong Zhao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. [Predictive Value of A miRNA Signature for Distant Metastasis in Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024
    Article
  6. Exosomal microRNAs in lung cancer: a narrative review.Translational cancer research · 2024
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. The dual role of microRNA (miR)-20b in cancers: Friend or foe?Cell communication and signaling : CCS · 2023
    Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Chengwei ZhouDepartment of Thoracic Surgery, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, China.
Zixuan ChenDepartment of Thoracic Surgery, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, China.
Lili ZhaoDepartment of Preventive Health Care, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, China.
Weijun ZhaoDepartment of Thoracic Surgery, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, China.
Yonggang ZhuDepartment of Thoracic Surgery, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, China.
Jiayuan LiuDepartment of Thoracic Surgery, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, China.
Xiaodong ZhaoDepartment of Thoracic Surgery, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, China.ORCID https://orcid.org/0000-0003-3633-1373
Ningbo University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-small-cell lung cancer (NSCLC) is a significant public health issue worldwide. The aim of our study was to develop a serum miRNA-based molecular signature for the early detection and prognosis prediction of NSCLC.

methodsThe significantly altered circulating miRNAs were profiled in GSE24709. The top ten upregulated miRNAs were miR-432, miR-942, miR-29c-5p, miR-601, miR-613, miR-520d-3p, miR-1261, miR-132-5p, miR-302b, and miR-154-5p, while the top ten downregulated miRNAs were miR-562, miR-18b, miR-9-3p, miR-154-3p, miR-20b, miR-18a, miR-487a, miR-20a, miR-103, and miR-144. Then, the top four upregulated serum miRNAs (miR-432, miR-942, miR-29c-5p, and miR-601) were validated by real-time quantitative PCR. The clinical significance of two candidate serum miRNAs, miR-942 and miR-601, was further explored.

resultsOur results showed that the expression levels of serum miR-942 and serum miR-601 were significantly upregulated in NSCLC. In addition, serum miR-942 and serum miR-601 showed better performance than CEA, CYFRA21-1, and SCCA for early diagnosis of NSCLC. Combining serum miR-942 and serum miR-601 enhanced the efficacy of detecting early-stage NSCLC. Moreover, high serum miR-942 and serum miR-601 were both associated with adverse clinical variables and poor survival. The NSCLC patients with simultaneously high serum miR-942 and serum miR-601 suffered worst clinical outcome, while those with simultaneously low serum miR-942 and serum miR-601 had most favorable outcome. The multivariate analysis showed that serum miR-942 and serum miR-601 were independent prognostic factors for NSCLC.

conclusionsTaken together, serum miR-942 and serum miR-601 might serve as a promising molecular signature for the early detection and prognosis prediction of NSCLC.

Indexed as

AgedBiomarkers, TumorCarcinoma, Non-Small-Cell LungCohort StudiesFemaleGene Expression Regulation, NeoplasticHumansLung NeoplasmsMaleMicroRNAsMiddle AgedPrognosisBiomarkers, TumorMicroRNAsearly diagnosisnon–small‐cell lung cancerprognosis predictionserum miR‐601serum miR‐942

Identifiers

PMID33463758
PMCPMC7676218
OpenAlexW3048099851

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.